PX1 Research has launched a line of US-manufactured sublingual peptide strips designed for needle-free research applications, featuring formulations including Retatrutide, Tirzepatide, and BPC-157. This move signals a shift in how academic and institutional researchers access peptide compounds, moving away from injectable formats toward a non-invasive oral delivery method produced under domestic quality control standards.
The new strips are produced under current Good Manufacturing Practice (cGMP) protocols, with every batch undergoing High-Performance Liquid Chromatography (HPLC) purity verification, confirming 99% or greater purity across all formulations. Each product is accompanied by a Certificate of Analysis, providing researchers with documented evidence of batch composition before use. The decision to manufacture domestically reflects a broader emphasis on supply chain transparency, as researchers often require documentation trails that trace production conditions.
Among the available formulations, dissolving Retatrutide strips have drawn particular attention given the compound's presence in ongoing metabolic and weight regulation research. Tirzepatide and BPC-157 are also included, extending coverage to compounds associated with glucose regulation and tissue repair research, respectively. The sublingual delivery format allows the strip to dissolve under the tongue, enabling absorption without needles or syringes. For research environments where non-invasive administration is a design requirement—whether due to protocol specifications, institutional review considerations, or participant-facing study designs—this format addresses a logistical gap that injectable formats cannot.
The full product line is accessible through PX1 Research, with specific information on dissolving Retatrutide strips available directly on the product page. These sublingual peptide strips are specifically designed for academic and institutional research contexts, not for clinical, therapeutic, or human consumption. Rather, the product addresses demand from researchers requiring compounds in a format compatible with non-invasive study designs, where traditional needle-based administration would introduce procedural variables or ethical complications.
The inclusion of BPC-157 alongside GLP-1 receptor agonist-class compounds such as Retatrutide and Tirzepatide signals that the line is intended to serve a range of research disciplines. Each compound presents distinct molecular properties, and the sublingual strip format has been adapted to accommodate the specific stability and absorption characteristics relevant to each formulation.
